ABSTRACT
Objective: Multiple factors have been studied in association with disease severity in COVID-19. The cycle threshold (Ct) value of polymerase chain reaction (PCR) can reflect viral load in the specimens. In this study, we aimed to evaluate the effect of the Ct value on clinical course and mortality in COVID-19 patients. Methods: Adult patients who tested positive for SARS-CoV-2 with PCR test and who were hospitalized with COVID-19-related symptoms between August 1, 2020, and November 30, 2020, were included in the study. In addition, Ct value, demographic and clinical data (length of hospital stay, need for admission to intensive care unit (ICU), need for mechanical ventilation (MV), and mortality) were reviewed retrospectively. Results: 117 patients were included in the study. The mean Ct value was 22.37 +/- 4.72 (11.07-34.06). There was no significant difference in the mean Ct values between the patients who needed ICU admission and those who did not. When the patients were evaluated by dividing them into three groups according to their Ct values, as < 20, between 20-24 and >24;there was no significant difference between these three groups in terms of severity of pneumonia, laboratory parameters (D-dimer, Neutrophil/Lymphocyte ratio, C-reactive protein, lymphocyte count), length of hospital stay, need for ICU admission, need for MV and mortality. When the patients were divided into two groups with Ct values as <23.3 and >= 23.3, no significant difference was found between the groups regarding ICU need, MV need, and 28-day mortality rates. Conclusion: Most of the studies in the literature about Ct value and its effect on clinical course indicate that lower Ct values are potentially associated with worse outcomes in COVID-19. However, there are also studies reporting that the Ct value does not reflect the severity of the disease. We did not find a correlation between Ct value and laboratory markers, length of hospital stay, the severity of pneumonia, need for ICU admission or MV, and mortality in COVID19 patients in this presented study.
ABSTRACT
Objective: Multiple factors have been studied in association with disease severity in COVID-19. The cycle threshold (Ct) value of polymerase chain reaction (PCR) can reflect viral load in the specimens. In this study, we aimed to evaluate the effect of the Ct value on clinical course and mortality in COVID-19 patients. Methods: Adult patients who tested positive for SARS-CoV-2 with PCR test and who were hospitalized with COVID-19-related symptoms between August 1, 2020, and November 30, 2020, were included in the study. In addition, Ct value, demographic and clinical data (length of hospital stay, need for admission to intensive care unit (ICU), need for mechanical ventilation (MV), and mortality) were reviewed retrospectively. Results: 117 patients were included in the study. The mean Ct value was 22.37 +/- 4.72 (11.07-34.06). There was no significant difference in the mean Ct values between the patients who needed ICU admission and those who did not. When the patients were evaluated by dividing them into three groups according to their Ct values, as < 20, between 20-24 and >24;there was no significant difference between these three groups in terms of severity of pneumonia, laboratory parameters (D-dimer, Neutrophil/Lymphocyte ratio, C-reactive protein, lymphocyte count), length of hospital stay, need for ICU admission, need for MV and mortality. When the patients were divided into two groups with Ct values as <23.3 and >= 23.3, no significant difference was found between the groups regarding ICU need, MV need, and 28-day mortality rates. Conclusion: Most of the studies in the literature about Ct value and its effect on clinical course indicate that lower Ct values are potentially associated with worse outcomes in COVID-19. However, there are also studies reporting that the Ct value does not reflect the severity of the disease. We did not find a correlation between Ct value and laboratory markers, length of hospital stay, the severity of pneumonia, need for ICU admission or MV, and mortality in COVID-19 patients in this presented study.
ABSTRACT
Objective: Multiple factors have been studied in association with disease severity in COVID-19. The cycle threshold (Ct) value of polymerase chain reaction (PCR) can reflect viral load in the specimens. In this study, we aimed to evaluate the effect of the Ct value on clinical course and mortality in COVID-19 patients. Method(s): Adult patients who tested positive for SARS-CoV-2 with PCR test and who were hospitalized with COVID-19-re-lated symptoms between August 1, 2020, and November 30, 2020, were included in the study. In addition, Ct value, demographic and clinical data (length of hospital stay, need for admission to intensive care unit (ICU), need for me-chanical ventilation (MV), and mortality) were reviewed retrospectively. Result(s): 117 patients were included in the study. The mean Ct value was 22.37+/-4.72 (11.07-34.06). There was no significant difference in the mean Ct values between the patients who needed ICU admission and those who did not. When the patients were evaluated by dividing them into three groups according to their Ct values, as < 20, between 20-24 and >24;there was no significant difference between these three groups in terms of severity of pneumonia, laboratory parameters (D-dimer, Neutrophil/Lymphocyte ratio, C-reactive protein, lymphocyte count), length of hospital stay, need for ICU admission, need for MV and mortality. When the patients were divided into two groups with Ct values as <23.3 and >=23.3, no significant difference was found between the groups regarding ICU need, MV need, and 28-day mortality rates. Conclusion(s): Most of the studies in the literature about Ct value and its effect on clinical course indicate that lower Ct values are potentially associated with worse outcomes in COVID-19. However, there are also studies reporting that the Ct value does not reflect the severity of the disease. We did not find a correlation between Ct value and laboratory markers, length of hospital stay, the severity of pneumonia, need for ICU admission or MV, and mortality in COVID-19 patients in this presented study. Copyright © 2022, DOC Design and Informatics Co. Ltd.. All rights reserved.
ABSTRACT
Introduction: Clinical picture of Coronavirus disease-2019 (COVID-19) ranges from mild respiratory symptoms to severe respiratory failure and death. To determine the severity of the disease;lymphocyte count, lactate dehydrogenase (LDH), C-reactive protein (CRP), D-dimer and interleukin-6 (IL-6) levels are the parameters that are used. In this study, it was aimed to evaluate effect of LDH/lymphocyte ratio on prognosis and whether there was a correlation between LDH/lymphocyte ratio and IL-6 in hospitalized patients with COVID-19. Materials and Methods: Patients who were aged 18 years and older, were positive for Severe acute respiratory syndrome-Coronavirus-2 polymerase chain reaction test, had COVID-19 pneumonia findings on tomography, and hospitalized for at least three days were included in the study. Results: The mean age of the patients was 59.35±15.23 year and 56 (59.6%) of patients were male. Fifty seven (60.6%) of the patients had comorbid diseases. The 14- and 28-day mortality rates were 14.9% and 27.7%, respectively. There was a statistically significant correlation between hospitalization in intensive care unit and LDH, lymphocyte count, LDH/lymphocyte ratio, CRP, highest D-dimer, initial IL-6, neutrophil/lymphocyte ratio, and highest IL-6 values (p<0.05). The IL-6 level, highest D-dimer level, LDH/lymphocyte ratio and CRP level of the patients who died were significantly higher than those who were survivors (p<0.05). A positive and significant correlation was found between the LDH/lymphocyte ratio and both the first admission and the highest IL-6 levels. In ROC analysis, LDH/lymphocyte ratio values of 0.53 and above [AUC: 0.758 (95% CI: 0.660-0.855)] were found to have a specificity of 61% and sensitivity of 70.7% in showing the IL-6 level of 80 pg/ml and above at first admission. Conclusion: In this study, a significant correlation was found between the LDH/lymphocyte ratio and the IL-6 values. As a result of this study, even if IL-6 cannot be measured, the ratio of LDH/lymphocyte that can be measured in most centers, is thought to be an important marker in predicting poor clinical course.